GSK and Flagship Pioneering partner to discover novel medicines and vaccines
- Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
- Initial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunology
- GSK and Flagship to jointly fund up to
$150 million upfront
This alliance brings together GSK's disease area expertise and development capability with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.
GSK and Flagship will initially fund up to
About Flagship Pioneering
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK enquiries |
|
|
|
Media: |
|
+44 (0) 20 8047 5502 |
( |
|
|
+44 (0) 20 8047 5502 |
( |
|
|
+1 202 603 5003 |
( |
|
|
+1 215 370 4680 |
( |
|
|
|
|
Investor Relations: |
|
+44 (0) 7717 618834 |
( |
|
|
+44 (0) 20 8047 2406 |
( |
|
|
+44 (0) 7990 339653 |
( |
|
|
+44 (0) 7385 415719 |
( |
|
|
+44 (0) 7803 050238 |
( |
|
|
+44 (0) 7796 707505 |
( |
|
|
+1 215 751 7002 |
( |
|
|
+1 215 751 4855 |
( |
Flagship enquiries
press@flagshippioneering.com
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q1 Results for 2024.
Registered in
No. 3888792
Registered Office:
Brentford,
TW8 9GS
View original content to download multimedia:https://www.prnewswire.com/news-releases/gsk-and-flagship-pioneering-partner-to-discover-novel-medicines-and-vaccines-302208162.html
SOURCE Flagship Pioneering